Enhancement of the antitumor effect of HER2‐directed CAR‐T cells through blocking epithelial‐mesenchymal transition in tumor cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Enhancement of the antitumor effect of HER2‐directed CAR‐T cells through blocking epithelial‐mesenchymal transition in tumor cells

Published:2020-07-09 Issue:8 Volume:34 Page:11185-11199
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Zhang Peng‐Fei¹,Huang Yong²,Liang Xiao¹,Li Dan²,Jiang Lin²,Yang Xiao²,Zhu Min²,Gou Hong‐Feng¹,Gong You‐Ling¹,Wei Yu‐Quan¹²,Li Qiu¹²,Wang Wei²

Affiliation:

1. Department of Medical Oncology Cancer Center, State Key Laboratory of Biotherapy West China HospitalSichuan University Chengdu China

2. State Key Laboratory of Biotherapy Collaborative Innovation Center for Biotherapy West China HospitalSichuan University Chengdu China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202000080RR

Reference51 articles.

1. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells

2. CD19 chimeric antigen receptor T cell therapy for haematological malignancies

3. CD19, from bench to bedside

4. FDA Approval of Tisagenlecleucel

5. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies;Biomedicine & Pharmacotherapy;2024-09

2. CAR-T cell technologies that interact with the tumour microenvironment in solid tumours;Expert Review of Clinical Immunology;2024-07-17

3. Prospects and challenges of CAR-T in the treatment of ovarian cancer;International Immunopharmacology;2024-05

4. Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential;Cancers;2023-12-26

5. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?;Current Treatment Options in Oncology;2023-07-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3